Cancer Family
Invasive Malignant Neoplasm
CI-CAN-00000213Explore in graph →
604 active trials9 approved drugs37 evidence items
- NCIt
- C8505
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000213Explore in graph →
Clinical trials
1,820 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01681368 | Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer | terminated | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 30, 2017 | clinicaltrials |
| NCT01175343 | RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 2 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT03038321 | Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects? | unknown | Phase 4 | 150 | Mansoura UniversityOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT03121768 | A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | unknown | — | 761 | Mansoura UniversityOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT00170157 | Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | completed | Phase 2 | 112 | Mayo ClinicOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT01068509 | Ovarian Cancer Vaccine for Patients in Remission | completed | Phase 2 | 63 | Prima BioMed LtdINDUSTRY | 2 | May 11, 2017 | clinicaltrials |
| NCT02077569 | AKT Inhibitor in Oestrogen Positive Breast Cancer(STAKT) | completed | Phase 2 | 48 | University of NottinghamOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT02742428 | Preoperative Ascites Drainage Versus Standard Care for Patients With Advanced Ovarian Cancer | suspended | N/A | 40 | Gdynia Oncology CenterOTHER_GOV | 1 | May 2, 2017 | clinicaltrials |
| NCT01228084 | Sulforaphane in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01494012 | Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01913015 | Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 1 | 3 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02840162 | Pre-Prostatectomy Celecoxib or Placebo | terminated | Phase 2 | 34 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01138137 | N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer | withdrawn | Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 21, 2017 | clinicaltrials |
| NCT00118092 | 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT02218502 | Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses(SUBSONiC) | terminated | N/A | 50 | Maastricht University Medical CenterOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01050842 | Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer | completed | Early Phase 1 | 18 | Mayo ClinicOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT00408681 | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant(GVHD) | completed | N/A | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT00058084 | Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01060085 | Digital Breast Tomosynthesis Versus Contrast Enhanced Magnetic Resonance Imaging (MRI) for Breast Cancer Staging | completed | — | 51 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT02323568 | Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.(VIVROVAIRE 2) | completed | N/A | 179 | Centre Francois BaclesseOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00879619 | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 4 | John P. FruehaufOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT02199418 | Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer(SHPD001) | completed | Phase 2 | 132 | RenJi HospitalOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT01521143 | Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment(CANVAS) | terminated | Phase 2 | 91 | Prima BioMed LtdINDUSTRY | 2 | Dec 14, 2016 | clinicaltrials |
| NCT00314678 | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer | completed | Phase 2 | 40 | John P. FruehaufOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00598858 | Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate(2007-5904) | withdrawn | Phase 2 | 0 | John P. FruehaufOTHER | 0 | Dec 8, 2016 | clinicaltrials |
| NCT02035345 | Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment | terminated | Phase 4 | 15 | Massachusetts General HospitalOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT01347788 | Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Nov 28, 2016 | clinicaltrials |
| NCT02333890 | A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer(CUBiC) | unknown | Phase 2 | 60 | Ottawa Hospital Research InstituteOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02964351 | microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer | unknown | — | 120 | Assuta Medical CenterOTHER | 0 | Nov 16, 2016 | clinicaltrials |
| NCT02244580 | Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit "MammaTyperTM" | completed | N/A | 1,010 | BioNTech Diagnostics GmbHINDUSTRY | 0 | Nov 7, 2016 | clinicaltrials |
| NCT00897442 | Collecting Tumor Samples From Patients With Gynecological Tumors | completed | — | 275 | Gynecologic Oncology GroupNETWORK | 1 | Oct 28, 2016 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT01630018 | Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial | completed | Phase 2 | 141 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Sep 22, 2016 | clinicaltrials |
| NCT02244502 | Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) | unknown | Phase 1 / Phase 2 | 31 | NovoCure Ltd.INDUSTRY | 4 | Sep 21, 2016 | clinicaltrials |
| NCT02083536 | LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma | withdrawn | Phase 1 | 0 | University of MiamiOTHER | 0 | Aug 10, 2016 | clinicaltrials |
| NCT00602277 | Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy | completed | Phase 1 | 70 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT01325311 | Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02595021 | Total/Subtotal Colectomy in Ovarian Cancer | unknown | Phase 2 | 80 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 | clinicaltrials |
| NCT01391351 | Search for Predictors of Therapeutic Response in Ovarian Carcinoma(miRSa) | completed | N/A | 107 | Centre Francois BaclesseOTHER | 1 | Jul 21, 2016 | clinicaltrials |
| NCT00635050 | Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin | completed | Phase 2 | 32 | University of Alabama at BirminghamOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT01283035 | A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00486668 | A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer | unknown | Phase 3 | 529 | NSABP Foundation IncNETWORK | 3 | Jun 6, 2016 | clinicaltrials |
| NCT00321646 | Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy | completed | Phase 2 | 42 | Mary-Ellen Taplin, MDOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT01447706 | A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers | completed | Phase 2 | 223 | Merrimack PharmaceuticalsINDUSTRY | 1 | May 12, 2016 | clinicaltrials |
| NCT02728492 | Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | completed | Phase 1 | 51 | NewVac LLCINDUSTRY | 1 | May 3, 2016 | clinicaltrials |
| NCT01219790 | ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma(GEMO) | completed | Phase 1 | 30 | Institut Cancerologie de l'OuestOTHER | 1 | Apr 19, 2016 | clinicaltrials |
| NCT00671788 | A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | completed | Phase 2 | 35 | Gynecologic Oncology GroupNETWORK | 1 | Apr 15, 2016 | clinicaltrials |
Data updated 23 days agoSource updated May 30, 2017source: clinicaltrials